Educating payers and providers on biosimilar clinical and economic evidence Educating payers and providers on biosimilar clinical and economic evidence Introduction to Regulatory Affairs in Biosimilar Market Access Biosimilars represent a significant advancement in biologics, offering more cost-effective alternatives to original biologic products. As the biosimilar market expands, understanding regulatory expectations and integrating them into payer strategies becomes paramount for regulatory professionals. In this article, we aim to elucidate the interaction of different regulatory frameworks in the US, EU, and UK, alongside evidence requirements to facilitate market access, effectively addressing the interests of payers. Legal and Regulatory Basis Understanding the…

Aligning launch sequencing, pricing and payer outreach for biosimilar success Aligning launch sequencing, pricing and payer outreach for biosimilar success Biosimilars represent a growing segment of the pharmaceutical market, offering the potential for significant cost savings and improved patient access across various therapeutic areas. However, navigating the complex landscape of regulatory requirements, payer strategies, and market access is critical for successful biosimilar launch and commercialization. This article serves as a comprehensive regulatory explainer manual, detailing the essential components for aligning launch sequencing, pricing, and payer outreach for biosimilars in the US, UK, and EU markets. Context Regulatory Affairs (RA) professionals…

Regulatory and legal constraints on biosimilar promotion and payer engagement Regulatory and Legal Constraints on Biosimilar Promotion and Payer Engagement The biosimilar market is rapidly evolving, subject to a complex array of regulatory frameworks, payer strategies, and legal considerations. For professionals in regulatory affairs, it is vital to understand the intricacies of market access, pricing, and engagement with U.S. payers. This article provides a comprehensive overview of the existing regulations and guidelines governing biosimilars, with a focus on the U.S., UK, and EU frameworks. Regulatory Context Biosimilars are biologics that are highly similar to an already approved reference biologic, having…

Global pricing and market access lessons that apply to US biosimilars Global pricing and market access lessons that apply to US biosimilars Biosimilars represent a significant advancement in the biopharmaceutical industry, particularly in offering cost-effective alternatives to existing biologic therapies. Understanding the regulatory landscape surrounding biosimilars, especially regarding market access and pricing considerations for U.S. payers, is critical for professionals working in Regulatory Affairs (RA), Clinical, Commercial, and Health Economics and Outcomes Research (HEOR). This article serves as a detailed regulatory explainer manual, breaking down the relevant regulations, guidelines, and agency expectations related to biosimilar market access and pricing strategies….

KPIs to measure biosimilar market access performance and ROI in the US KPIs to Measure Biosimilar Market Access Performance and ROI in the US Context As the market for biosimilars expands in the United States, understanding and measuring their market access performance, pricing strategies, and return on investment (ROI) becomes crucial for regulatory affairs (RA) professionals. Biosimilars are biologic medical products highly similar to already licensed reference products and commonly used in various therapeutic areas. The regulatory framework governing biosimilars in the US is defined primarily by the Biologics Control Act (BCA), as amended by the Affordable Care Act (ACA),…